Multimeric Biotherapeutics Information

Multimeric Biotherapeutics, Inc. is an emerging biotechnology company centered on using proteins in the TNF SuperFamily (TNFSF). Its key technology is a patented method of making TNFSF ligands as highly active multi-trimer soluble proteins. The lead compound, MegaCD40L(tm), is a 2-trimer form of CD40L that is highly immunostimulatory. In preclinical studies, this protein has been shown to be a powerful immune adjuvant for new classes of vaccines and an effective stimulant for inducing the immune destruction of tumors while sparing normal tissue. Follow-on products include highly active forms of 4-1BBL (CD137L) and OX40L (CD134L). The initial clinical target is ovarian cancer treatment using MegaCD40L, supported by an NIH grant. Other studies, also supported by an NIH grant, will test MegaCD40L as a vaccine adjuvant.